OrbiMed is a healthcare-focused investment firm based in New York, founded in 1989, with approximately $5 billion in assets under management. It engages in private equity, venture capital, and growth investments across the global healthcare landscape, spanning biopharmaceuticals, biotechnology, life sciences tools, medical devices, diagnostics, health care services, and digital health. The firm invests across the development spectrum, from startup ventures to mature companies, and pursues opportunities worldwide, including North America, Europe, Asia, Israel and India, leveraging a long-standing specialization in the sector. Through its diversified capital programs, OrbiMed partners with management to advance innovative therapies, tools, and services that address significant medical needs.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages USD and RMB funds totaling about 9.5 billion in capital and backs early- and growth-stage technology, consumer, and healthcare companies. The firm has backed more than 530 portfolio companies, with over 200 exits via IPOs or M&A, and more than 70 unicorn or super unicorn companies.

RA Capital Management is a Boston-based investment firm that specializes in life sciences and healthcare companies. The firm provides investment management and venture capital services, backing companies developing drugs, medical devices, diagnostics, and biotech tools. Its team combines expertise in biology, chemistry, and medicine with industry and business development experience. RA Capital supports companies across multiple stages, from seed funding to growth financings, including private and public rounds, and often takes board seats and seeks co-investment opportunities. Through its activity, it aims to identify technologies with potential to advance prevention and treatment, genetic testing and personalized medicine, and other patient-focused innovations.

SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995, that focuses on seed to growth investments in deep technology across health, environmental tech, hardware, robotics, and cross border software, with a particular emphasis on Asia. The company runs accelerator style startup development programs, including HAX and IndieBio, which provide facilities, engineering resources, and lab equipment to help founders accelerate product development, acquire customers, and attract later stage funding. SOSV pursues a limited number of high potential startups, offering extensive hands on support to speed commercialization and scale, and aims to back innovations that improve human and planetary health.

Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and sells medicines across neuroscience, cardiometabolic diseases, cancer, and immunology. It operates manufacturing and research facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in roughly 135 countries. The portfolio includes Verzenio, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant, reflecting a diversified, science‑driven approach. In addition to human medicines, Lilly conducts research in animal health to treat animal diseases and support agricultural productivity. The company maintains a strong emphasis on research and development to address unmet medical needs and to bring innovative therapies to patients worldwide.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Novo Nordisk is a global healthcare company that develops, manufactures, and distributes insulin and other diabetes medicines to treat chronic diseases. It pursues scientific breakthroughs and aims to expand access to its medicines, with the ultimate goal of preventing and curing disease.

Morningside is a Boston-based investment firm founded in 1986 as a family office for the Chan family. It makes venture capital investments in companies with novel science and technology, with deep expertise in life sciences, digital health, artificial intelligence, materials, and technology. The firm takes a long-term approach to building companies and emphasizes ethical conduct. In addition to its investment activities, Morningside supports charitable initiatives in education, research and healthcare, including collaborations with Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

New Enterprise Associates is a U.S.-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across stages and geographies, supporting startups from seed to growth. The firm operates globally with investments in the United States, Asia, and Brazil among others, and has a long track record of portfolio IPOs and acquisitions. It has over $19 billion in cumulative committed capital.

Deerfield Management is a New York-based investment management firm founded in 1994 that focuses on healthcare. It engages in long-term structured investments in both public and private healthcare companies, and operates across investment activities, information services, and philanthropy. It acts as an investment adviser and supports private and public investments across life sciences, medical devices, diagnostics, digital health, and health services.

Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, established in 2013. It targets individual accredited investors who previously had limited access to venture capital by enabling alumni from top entrepreneurial schools to invest together in ventures led by fellow alumni. The firm backs companies with an alumni connection and an institutional lead investor with sector expertise. It offers focused funds that provide accredited investors access to a diversified venture portfolio by type, sector, stage, and geography. The organization engages in seed, early-stage, and late-stage pre-IPO investments across technology, consumer, financial services, health care, life sciences, and other sectors.

ARCH Venture Partners is a United States-based venture capital firm founded in 1986 and headquartered in Chicago, Illinois. The firm focuses on science-driven companies, with a track record of commercializing technologies developed at academic research institutions and national laboratories. It primarily invests in life sciences, biotechnology, pharmaceuticals, healthcare technology, and related sectors, and also backs software, materials, clean tech, and information technology across early to growth stages. ARCH emphasizes relationships with scientists and entrepreneurs, often taking early stakes and supporting subsequent rounds to help market entry and scale. The firm has raised multiple venture funds totaling several billion dollars and maintains a national and international reach with offices across North America.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. The firm backs entrepreneurs with venture assistance, strategic guidance, and capital, focusing on bold, early-stage technology companies. It invests across sectors including AI, climate and sustainability, enterprise software, consumer technologies, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technologies. Based in Menlo Park, the firm manages several funds to support startups across stages, prioritizing ventures that address large markets and have potential for significant social and economic impact.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada, the United States and Europe. The firm invests across the healthcare sector at all stages, with an emphasis on discovery and development of novel therapeutics, and portfolios spanning biotechnology, pharmaceuticals, life sciences, healthcare devices and healthtech. Versant combines deep investment, operating and scientific expertise to support entrepreneurs through hands-on company building. It has backed more than 65 portfolio companies that have achieved acquisitions or IPOs.

High-Tech Gründerfonds is a Germany-based seed and early-stage venture capital firm focused on technology companies in Germany. Based in Bonn with an additional office in Berlin, it operates as a public-private partnership that supports high-tech startups across information technology, software, hardware, life sciences, chemistry and related fields. HTGF provides initial funding and follow-on capital to eligible young companies, often taking minority stakes and participating as lead or co-investor, while offering hands-on guidance from experienced investment managers and startup experts. Since its founding in 2005, the firm has backed numerous startups and facilitated the growth of portfolio companies through multiple funds aimed at early stages. The model combines both public support, involving government and financial institutions, with private investor participation to nurture startups from concept to market.

General Catalyst is a venture capital firm founded in 2000 that provides early-stage and growth equity investments in technology companies. It supports portfolio companies with momentum and mentorship to accelerate growth toward long-term success and typically engages across seed to growth stages, potentially taking minority or majority stakes. The firm targets a broad range of sectors enabled by software and technology, including consumer, enterprise, fintech, crypto, healthcare IT, and related areas, and maintains a multi-region presence with offices in North America and Europe to back companies as they scale globally.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization founded in 1982 that supports the region's technology ecosystem. Based in Philadelphia, it acts as a capital provider and catalyst for early-stage and growing technology companies across information technology, health, and physical sciences by offering seed-stage funding and related resources to accelerate commercialization. The organization facilitates university–industry partnerships and regional initiatives that connect scientific research with market opportunities, with the aim of creating jobs and strengthening entrepreneurial communities in Southeastern Pennsylvania. Through its programs and partnerships, it supports adoption of new technologies and helps build a robust regional innovation ecosystem.

Polaris Partners is a Boston-based venture capital firm with offices in Boston and San Francisco that backs technology and life sciences companies across the United States and Europe. Founded in 1996, the firm partners with repeat entrepreneurs to support companies through multiple stages, from inception to growth, with a focus on software, healthcare information technology, digital health, life sciences, biotechnology, pharmaceuticals, genomics, and related sectors. Its investments span the business-to-business and business-to-consumer markets, software as a service, and other technology-enabled solutions, aiming to build durable platform companies and address significant needs in healthcare and technology.

Samsara BioCapital is a Palo Alto-based venture capital firm founded in 2016 that focuses on the healthcare sector, including biotechnology, pharmaceuticals, oncology, and life sciences. The firm seeks opportunities in the United States and provides investment advisory services as part of its activities, supporting companies developing innovative therapies and related technologies.

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage technology and healthcare investments and has backed landmark companies such as Apple Computer, Intel, Illumina, Gilead Sciences, Athenahealth, DoubleClick, Nest, SlideShare, and Tudou. The firm manages multiple funds and maintains a US-focused investment approach, supporting entrepreneurs across information technology, life sciences, and related sectors throughout their growth journey.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences from seed to later-stage investments. It backs startups, early-stage companies, corporate spin-offs and occasionally turnaround situations in biopharmaceuticals/biotech, medical devices, and industrial biotechnology. The firm typically takes a lead or cornerstone role, often serving as the first institutional investor in Series A rounds, and actively supports portfolio companies through formation and beyond, including board participation. The firm manages more than €2 billion in life sciences assets.

Redmile Group is a San Francisco-based private equity firm with an office in New York that focuses on investments in the healthcare sector, pursuing opportunities across venture, growth, and crossover stages to support healthcare companies with strategic capital and partnerships.

F-Prime Capital is a venture capital investment firm based in Cambridge, Massachusetts. Founded in 1969 with roots in Fidelity Investments, it backs entrepreneurs across technology and life sciences, investing in sectors such as crypto, enterprise information technology, fintech, frontier technologies, health information technology and services, medtech and therapeutics, with a global reach across the Americas, Europe and Asia.

Pfizer is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines across a broad range of therapeutic areas. It maintains an extensive portfolio of prescription drugs and vaccines, with notable products such as Prevnar 13, Ibrance, and Eliquis. The company serves customers worldwide, with substantial international and emerging-market sales. Through ongoing research and development, Pfizer pursues new treatments to address major diseases, including cancer and neurodegenerative conditions, and aims to improve patient outcomes by delivering safe, effective, and accessible therapies. Founded in 1849 and headquartered in the United States, Pfizer operates globally to advance health care through science, partnerships, and scalable manufacturing capabilities.

Antler is a global venture capital firm based in Singapore that backs early-stage technology companies. It runs incubation programs and provides a global community of co-founders, access to talent, expert advisors, expansion support, and capital to help startups grow. The firm targets a broad range of sectors, including healthcare, finance, software, energy, consumer and B2B technologies, and operates through regional programs across Europe, the United States, the United Kingdom, Southeast Asia, India, Africa, and beyond.

HBM Healthcare Investments is a Switzerland-based investment firm founded in 2001 and based in Zug. It concentrates on the healthcare sector, spanning human medicine, biotechnology, medical technology and diagnostics. The firm maintains a diversified portfolio that includes private companies, public companies, funds, cash and other assets, reflecting exposure across different stages and sectors within healthcare.

Vivo Capital is a healthcare-focused investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm operates a multi-strategy platform including growth equity, private equity, venture capital, and public equity, and invests across biopharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and healthcare services. It pursues opportunities globally, including the United States and China, and has invested in more than 290 companies. The team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts, and the firm manages about $5.8 billion in assets.

Andreessen Horowitz is a venture capital firm based in Menlo Park, California. Founded in 2009 by Marc Andreessen and Ben Horowitz, it funds software and technology companies across seed to growth stages, with emphasis on web and mobile applications, cloud infrastructure, enterprise software, fintech, consumer Internet, artificial intelligence, and biotech-adjacent ventures. The firm focuses on technology-enabled businesses and provides strategic support and networks to portfolio companies.

Kurma Partners is a Paris-based investment management company focused on funding innovation in healthcare and biotechnology across Europe. Established in 2009, it targets early-stage to development capital for life sciences companies and digital health ventures, spanning healthcare, biotechnology, and related technology sectors. The firm pursues a hands-on approach to support research-driven startups, leveraging connections with research institutes and hospitals to advance therapeutic and medical innovations. Through its activity as a private equity and venture investor, Kurma Partners seeks to back companies throughout their growth trajectory, from initial concept to market readiness, helping them navigate clinical development, regulatory pathways, and commercialization in the European market.

Mission BioCapital is a life science venture capital firm that backs early‑stage biotechnology companies. Based in Cambridge, Massachusetts, the firm draws on a leadership team with a long history of investing in and launching numerous early‑stage life science ventures. It operates in regions with strong research, discovery, and venture capital ecosystems and is known for providing deep expertise and active support to its portfolio companies.

Gaingels is a venture investment organization focused on LGBTQ+-founded and led companies and their allies, investing across stages from pre-seed to pre-IPO and maintaining a global portfolio. Founded in 2014 and based in New York, it operates as a syndicate with more than 130 portfolio companies and around $70 million deployed. The organization supports inclusive leadership by backing ventures that promote diverse C-suite and board representation and actively assists portfolio companies in recruiting diverse executive talent. It also fosters a global community of industry leaders, investors, operators, and entrepreneurs who pursue positive social change through business and successful investments.

Right Side Capital Management is a San Francisco-based venture capital firm founded in 2010 that invests in early-stage technology startups. It specializes in pre-seed and seed rounds for capital-efficient companies, with a focus on the United States and Canada and occasional activity in Western Europe, Israel, Australia, and New Zealand. The firm typically makes 75 to 100 investments per year, with round sizes from 50,000 to 500,000 and pre-money valuations ranging from 1,000,000 to 3,500,000. Portfolio companies are typically located outside the San Francisco Bay Area and New York City, and the firm aims to provide a clear yes or no on opportunities within about two weeks.

Legend Capital is a Beijing-based venture capital firm and the investment arm of Legend Holdings, established in 2001 to become a leading venture capital manager in China. It manages up to about US$700 million across four funds and focuses on high-growth ventures with operations in China or markets related to China, particularly in early-stage information technology including network applications and services, outsourcing and professional services, and infrastructure components such as IC design, as well as mid-market growth in consumer goods, clean technology, healthcare, equipment manufacturing, and modern services. As an active investor, Legend Capital provides portfolio companies with strategic resources, business development support, and market guidance to help them scale in the Chinese market. Notable investments include Joyo.com, SinoCom, Solarfun Power, Spreadtrum Communications, China Sunshine Paper, and VanceInfo, among others.

Takeda is a global pharmaceutical company, and Japan's largest drug maker, focused on researching, developing, manufacturing, marketing and distributing prescription medicines and related therapies. Its core therapeutic areas include oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which together account for the majority of revenue. The company operates globally with a diversified geographic mix, deriving more than half of sales from the United States, about 20% from Japan, and about 20% from Europe and Canada. Takeda pursues innovation across drug discovery and development, maintains a portfolio spanning pharmaceuticals and biologics, and emphasizes patient-centric care and collaboration with researchers to advance clinical proof concepts and address unmet medical needs.

The Column Group is a venture capital firm focused on building the next generation of biotechnology companies. Based in San Francisco, California, the firm invests in seed- and early-stage biotechnology, life sciences, and technology-driven startups in the United States, with a particular emphasis on oncology and drug discovery. It supports companies developing new therapies and scientific platforms aimed at unmet medical needs, pursuing a long-term approach to enable multiple product opportunities rather than quick exits. Its portfolio interests include cancer, inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system diseases, reflecting a focus on translating science into therapeutics.

IMM Investment is a Seoul-based independent private equity and venture capital firm established in 1999. The company engages in mezzanine and growth investments and pursues opportunities in mergers and acquisitions, venture capital, corporate restructuring, private equity, industry consolidation, management buyouts, spin-offs, recapitalizations, and cross-border transactions. It concentrates on medium-sized companies operating in information technology infrastructure, wireless communications, software, contents, and other technology-enabled sectors, with a particular emphasis on information technology, healthcare/biotech, and manufacturing. The firm typically takes an active role in governance and strategic direction and focuses on opportunities within South Korea and cross-border contexts. IMM Investment aims to support portfolio companies through growth, expansion, and consolidation, leveraging its long-standing relationships with institutional investors and investment professionals.

Casdin Capital is a New York-based investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin, the firm pursues private investments and research-driven opportunities across early- to late-stage companies in these sectors and is described as a venture capital firm and a registered investment adviser.

Atlas Venture is a Cambridge, Massachusetts–based venture capital firm founded in 1980 that specializes in life sciences and technology. It pursues seed-led venture creation and early-stage investments to build scalable companies in biopharmaceuticals, diagnostics, medical devices, and related biomedical technologies, as well as software and other technology sectors. The firm often leads investments and seeks board representation to support portfolio companies as they grow toward acquisition or public offerings. Atlas operates with dedicated life sciences and technology teams and maintains an international footprint across the United States and Europe.

Forbion is a Netherlands-based venture capital firm focusing on life sciences and bioeconomy companies across Europe and North America. It invests in a broad spectrum of sectors including pharmaceuticals, biotechnology, MedTech, autoimmune and inflammatory diseases, cardiovascular and metabolic disorders, CNS conditions, oncology, ophthalmology, orphan and rare diseases, and related environmental, food, and materials technologies. The firm pursues both early-stage and growth investments in life sciences and technology companies, providing capital and strategic support to advance drug development, medical devices, and other innovations in health and bioscience.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

StartUp Health is a health innovation platform founded in 2011 that supports a global portfolio of health technology companies through a network of entrepreneurs known as Health Transformers. Its mission is to achieve health moonshots by advancing solutions across Access to Care, Cost to Zero, Cure Disease, End to Cancer, Women’s Health, Children’s Health, Nutrition and Fitness, Brain Health, Mental Health and Happiness, Addiction, Longevity, and Pandemic Response. The organization oversees more than 330 portfolio companies across six continents and 26 countries, working with leading health systems and investors to accelerate adoption and impact. By connecting entrepreneurs with health systems, researchers, and investors, StartUp Health aims to improve the health and wellbeing of people worldwide and transform healthcare delivery over a multi-decade timeframe.

8VC is a technology and life sciences investment firm based in San Francisco that partners with founders to develop transformational technologies. The firm aims to create long-term economic and societal value through its investments, spanning healthcare, energy, consumer goods, financial services, infrastructure, information technology, manufacturing, enterprise, logistics, defense, and other sectors. By backing ambitious teams and providing strategic support, 8VC seeks to enable industry transformation and global innovation.

SV Health Investors is a United States‑headquartered healthcare and life sciences venture capital and growth equity firm. Formerly known as SV Life Sciences, it supports entrepreneurs who create breakthrough companies and treatments across biotech, medical devices, and healthcare services. With offices in Boston, San Francisco and London, the firm has over two billion dollars of capital under management across seven private healthcare funds and more than two decades of activity in the US and Europe.

Korea Investment Partners is a Seoul-based venture capital and private equity firm with decades of experience in funding bold, innovative entrepreneurs. It operates globally with offices in Shanghai, Beijing, and Sunnyvale and manages multiple funds totaling several billions of dollars in assets under management. As the venture capital and private equity arm of Korea Investment Holdings, KIP backs a broad range of sectors including information technology, healthcare, life sciences, manufacturing, mobility and gaming, as it seeks to help companies scale and commercialize new technologies. The firm emphasizes long-term value creation and has built a diversified portfolio across Asia and beyond.

European Investment Fund (EIF) is a public institution established in 1994 to improve access to finance for Europe's small and medium-sized businesses. It designs and develops venture capital and guarantee instruments to support SMEs and to catalyse private investment, aiming to build a robust European equity ecosystem. EIF engages in venture capital, growth capital, and guarantee operations, backing innovative entrepreneurs primarily in technology and life sciences, as well as across other sectors. Through cornerstone investments and fund participation, EIF seeks to crowd in private investors and stimulate venture activity across Europe. Its equity portfolio has grown substantially, with assets under management exceeding EUR 14 billion, reflecting its broad role in strengthening SME finance and supporting entrepreneurship and growth.

SR One Capital Management is the corporate venture capital arm of GlaxoSmithKline. Based in Redwood City, California, the firm, founded in 1985, makes global venture investments in life sciences, including biotechnology, healthcare, medical devices, and related information technology, seeking innovative science with potential to significantly improve medical care. As a registered investment adviser, it supports early- and growth-stage companies aligned with GlaxoSmithKline's scientific priorities and advances medical innovation.

Keiretsu Forum is an international investment community of accredited private equity investors, venture capitalists and corporate/institutional investors. Founded in San Francisco in 2000, it operates as a worldwide network that structures access to high-quality deal flow and investment opportunities through regional chapters across the United States, Europe and Asia. It is described as the world’s largest invitation-only angel investor network, with thousands of investor members who participate in funding opportunities for early- to growth-stage companies in technology, healthcare, energy, consumer products and other sectors. The forum emphasizes collaboration among members and partner resources to support due diligence, syndication and capital deployment, enabling private capital to back high-potential ventures.

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. Founded in 2018, the firm invests in life sciences and technology companies across biotechnology, diagnostics, digital health, environmental technologies, and related industries, including AI and machine learning-enabled therapeutics and medical technologies. It targets growth capital and early-stage opportunities, providing capital and strategic support to help scientific innovations reach the market. The firm operates as a registered investment adviser.

Omega Funds is a Boston-based venture capital firm that backs life sciences, biotechnology, health care technology and related software-enabled solutions. Founded in 2004, the firm invests across the United States and Europe, targeting pharmaceuticals, biotechnology, oncology, immunology, rare diseases, precision medicine, digital health, healthtech and cybersecurity. It manages multiple funds, including Omega Fund IV, V, VI and VII, and supports companies from early to growth stages. The firm serves as an investment adviser to its funds and seeks to build a diversified portfolio at the intersection of science and technology.